Novavax (NVAX) stock in focus as the U.S. FDA approves its COVID-19 vaccine Nuvaxovid for high-risk groups in the U.S. Read ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Novavax (NVAX) closed the most recent trading day at ... Elsewhere, the Dow saw a downswing of 2.48%, while the tech-heavy Nasdaq depreciated by 2.55%. Prior to today's trading, shares of the ...

Novavax (NVAX) closed the most recent trading day at ... At the same time, the Dow added 1.39%, and the tech-heavy Nasdaq gained 1.51%. Coming into today, shares of the vaccine maker had gained ...

Novavax (NVAX) came out with quarterly earnings of $2.93 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to loss of $1.05 per share a year ago. These figures are ...

Novavax NVAX reported first-quarter 2025 earnings of $2.93 per share, which beat the Zacks Consensus Estimate of 71 cents. In the year-ago quarter, the company reported a loss of $1.05 per share.

Novavax NVAX shares rallied 19.5% in the last trading session to close at $7.47. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session.

(RTTNews) - Novavax, Inc. (NVAX) reported net income for the first ... of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Novavax Inc (NVAX) reports a dramatic revenue increase and strategic collaborations, while navigating regulatory hurdles and ...

$170,000 of NOVAVAX INC lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Issues related to COVID-19 vaccines ...

Novavax (NasdaqGS:NVAX) recently reported a significant financial turnaround for Q1 2025, demonstrating substantial revenue growth and net income improvements. The amending of its collaboration ...